SAB BIO is a clinical-stage biopharmaceutical company developing multispecific human immunoglobulin G therapies (hIgG) to treat and prevent type 1 diabetes (T1D) and other autoimmune disorders.
Founded in 2014, we use advanced genetic engineering and proprietary antibody technology to develop novel therapeutics. Our lead candidate, SAB-142, is a potential disease-modifying treatment for autoimmune T1D, designed to delay onset and potentially prevent disease progression.
SAB-142 is being evaluated in clinical trials across the T1D disease continuum, including the SAFEGUARD study for those newly diagnosed in Stage 3 T1D and the investigator-led PRISE-hATG study for people up to 2 years from a Stage 3 T1D diagnosis.
SAB Corporate Presentation